Myriad Genetics is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests helping patients and healthcare providers make informed medical decisions across oncology, women's health, and mental health specialties. The company's core offerings include hereditary cancer risk assessment, companion diagnostics for cancer therapy selection, tumor profiling and residual disease detection, prenatal screening and carrier testing, and pharmacogenomic testing for psychiatric medication selection. Revenue is generated primarily through private insurance payors, with remaining revenue from Medicare, Medicaid, and patient out-of-pocket payments, with tests ordered by physicians across community practices, hospitals, and academic institutions.